Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 59 | SFEBES2018 | Next issue

Society for Endocrinology BES 2018

Glasgow, UK
19 Nov 2018 - 21 Nov 2018

Card image cap
The Society for Endocrinology BES will take place 19-21 Nov 2018 in Glasgow. Come and exchange knowledge, share experiences and strengthen collaborations across our global community of endocrinologists.

ea0059oc5.1 | Adrenal | SFEBES2018

Timed urinary steroid profiling of patients with different degrees of cortisol excess: a proposal for a new test for the diagnosis of Cushing’s syndrome

Prete Alessandro , Taylor Angela E , Schiffer Lina , Nestola Manuela , Pignata Luisa , Corsello Salvatore M , Arlt Wiebke

Background: Cushing’s syndrome (CS) is caused by endogenous cortisol excess and is associated with significant morbidity. Twenty-four-hour urinary cortisol is one of the most useful tools to diagnose CS although it has limitations, especially in “mild” and “subclinical” forms of cortisol excess. We hypothesized that given the diurnal rhythm of physiological cortisol secretion, night-time urinary glucocorticoid excretion should be lower than day-time ex...

ea0059oc5.2 | Adrenal | SFEBES2018

Residual adrenal function in autoimmune addison s disease effect of dual therapy with rituximab and depot tetracosactide

Napier Catherine , Gan Earn H , Mitchell Anna L , Gilligan Lorna C , Rees Aled , Moran Carla , Chatterjee Krishna , Vaidya Bijay , Arlt Wiebke , Pearce Simon HS

In patients with autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion; patients on long-term steroid replacement have increased morbidity, reduced life expectancy and poorer quality of life. Recent early-phase studieshave demonstrated that some endogenous steroidogenic function – Residual Adrenal Function (RAF) - is maintained at the point of diagnosis in a proportion of AAD patients; this...

ea0059oc5.3 | Adrenal | SFEBES2018

11βHSD1 mediates therapeutic glucocorticoid-induced muscle atrophy in chronic inflammatory disease

Webster Justine , Fenton Chloe , Lavery Gareth , Langen Ramon , Hardy Rowan

Objective: Therapeutic glucocorticoids (GCs) are commonly used in the treatment of chronic inflammatory disease. Unfortunately, their long-term administration is associated with deleterious systemic side effects including muscle atrophy. 11 beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) activates glucocorticoids within muscle, is increased with inflammation, and has previously been shown to mediate GC induced muscle wasting. We examined the role of 11 beta-hydroxyster...

ea0059oc5.4 | Adrenal | SFEBES2018

Glucocorticoid receptor-mediated signalling inhibits mesenchymal cell proliferation via repression of the V1 isoform of versican during mouse lung development

Short Kelly , Bird Anthony , Seow Bennet , Cole Timothy

Glucocorticoid (GC) signalling via the glucocorticoid receptor (GR) is essential for normal lung development. Previous work using conditional mouse knockouts of the GR gene established that GR activity in the mesenchymal compartment of the lung is critical for normal respiratory development. Screens for GC-target genes with conditional mesenchymal GR deficient mouse lung (GRmeskO) identified Versican (Vcan), an important extracellular matrix (ECM) component and cell proliferat...

ea0059oc5.5 | Adrenal | SFEBES2018

Androgen modulation of mouse uterus: a tissue-based bioassay for testing endogenous and synthetic androgen receptor modulators (SARMs)

Simitsidellis Ioannis , Kelepouri Olympia , Gibson Douglas A , Esnal-Zufiaurre Arantza , Saunders Philippa TK

The uterus is an androgen-responsive tissue and AR is expressed in cells within the endometrium and myometrium. We have demonstrated that treatment of ovariectomised mice with the potent androgen dihydrosterone (DHT) induces a uterotrophic response with changes in expression of genes involved in cell-cycle progression, Wnt signalling and an expansion of the glandular epithelium. Selective androgen receptors modulators (SARMs) are AR ligands in development as potential therapeu...

ea0059oc5.6 | Adrenal | SFEBES2018

Therapeutic glucocorticoids prevent local and systemic bone loss in the TNF-tg model of chronic inflammatory disease

Fenton Chloe , Fareed Syeda , Naylor Amy , Nanus Dominika , Cooper Mark , Raza Karim , Lavery Gareth , Hardy Rowan

Both therapeutic glucocorticoids (GCs) and chronic inflammation are powerful inducers of systemic bone loss, resulting in osteoporosis and increased morbidity. Whilst GCs suppress inflammation, it is unclear how these factors interact to determine net bone metabolism. We investigated the balance between osteo-protective and osteo-destructive properties of GCs in the TNF-tg model of chronic inflammatory disease. Wild-type (WT) and TNF-tg mice were treated with corticosterone (1...